Search

Your search keyword '"Chung, Stephen S."' showing total 410 results

Search Constraints

Start Over You searched for: Author "Chung, Stephen S." Remove constraint Author: "Chung, Stephen S."
410 results on '"Chung, Stephen S."'

Search Results

1. Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence.

2. RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax

7. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial

10. Identifying patients at risk for hereditary myeloid malignancy syndromes incorporating a novel, self‐administered questionnaire to an initial screening platform

11. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies

13. Abstract 5925: Prevalence of clonal hematopoiesis in patients with monoclonal gammopathy of undetermined significance

14. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience

17. Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort

18. CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse

23. Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes

24. Treatment Patterns and Outcomes of Peripheral T-Cell Lymphoma (PTCL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution: Does Consolidative Autologous Stem Cell Transplantation (ASCT) Make a Difference?

25. Impact of First-Line Consolidative Autologous Hematopoietic Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL): A 'Real-World' Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

27. Clonal Hematopoiesis and Heart Failure with Preserved Ejection Fraction

28. Prevalence of Clonal Hematopoiesis in Patients with Monoclonal Gammopathy of Undetermined Significance

29. Impact of Bridging Therapy on Infectious Complications Post CAR T-Cell Therapy: The UT Southwestern Experience

30. Post-Transplant Cyclophosphamide Associated with Increased Early Mixed Donor Chimerism in Myeloid Malignancies; A Single-Center Experience

31. Do Monoclonal Antibody Therapies Improve 'Real-World' Outcomes of COVID-19 in Patients with Lymphoid Malignancies? the UT Southwestern Experience

32. Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

35. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia

36. Real World Efficacy of Luspatercept in Patients with Lower-risk Myelodysplastic Syndromes/Neoplasms (LR-MDS); a Single Center Study in a Heavily Pretreated Cohort

37. MDS-199 Real World Efficacy of Luspatercept in Patients with Lower-risk Myelodysplastic Syndromes/Neoplasms (LR-MDS); a Single Center Study in a Heavily Pretreated Cohort

40. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

43. Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single-Center Retrospective Analysis

44. Utilization and Barriers to Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma: A ‘Real-World’ Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

46. A Phase II Study of Selinexor, a First-in-Class XPO1 Inhibitor, in Patients with Myelodysplastic Syndromes and Oligoblastic Acute Myeloid Leukaemia Refractory to Hypomethylating Agents

Catalog

Books, media, physical & digital resources